KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) EBT Margin (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed EBT Margin for 11 consecutive years, with 861.6% as the latest value for Q1 2025.

  • On a quarterly basis, EBT Margin changed N/A to 861.6% in Q1 2025 year-over-year; TTM through Dec 2025 was 4598.59%, a N/A change, with the full-year FY2025 number at 4598.59%, changed N/A from a year prior.
  • EBT Margin was 861.6% for Q1 2025 at Xenon Pharmaceuticals, up from 28588.64% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 228.88% in Q1 2022 to a low of 28588.64% in Q3 2022.
  • A 3-year average of 4736.05% and a median of 766.36% in 2021 define the central range for EBT Margin.
  • Biggest YoY gain for EBT Margin was 13440bps in 2022; the steepest drop was -2824086bps in 2022.
  • Xenon Pharmaceuticals' EBT Margin stood at 671.13% in 2021, then tumbled by -4160bps to 28588.64% in 2022, then surged by 97bps to 861.6% in 2025.
  • Per Business Quant, the three most recent readings for XENE's EBT Margin are 861.6% (Q1 2025), 28588.64% (Q3 2022), and 5820.52% (Q2 2022).